®
where phages go clinical
Development and clinical trials of a modern drug
to treat bacterial infections
PROJECT TIMELINE
August 2022 - Application for clinical trials successfully submitted to State Institute for Drug Control
December 2022 - Clinical trials approved by the State Institute for Drug Control
August 2023 - Clinical trials ready to start after last preclinical data has been gathered
October 2023 - First patients entered the clinical trials
®
-
is an alternative to antibiotics;
-
is an innovative biological medicine containing bacteriophages;
-
enables fast and effective treatment of wounds, injuries and ulcers contaminated with Staphylococcus aureus and Pseudomonas aeruginosa;
-
responses to the increasing antibiotic resistance, which is according to WHO one of the biggest threats to global health;
-
has been successfully developed by the Czech biotech company
BACTERIOPHAGES
-
also known informally as phages, are viruses that infects bacteria and destroy their cells;
-
were discovered already in 1896 and described in 1915 - even before penicillin (1928);
-
are highly selective - they only attack their host bacteria, they are harmless to other microorganisms, people, animals, and plants;
-
are a natural part of the microbial world and are the good guys of the virology world;
-
effectively fight also the most dangerous forms of antibiotic-resistant bacteria.
MB PHARMA
-
is a Czech company focused on research, development and innovation in the field of microbiology and biotechnology;
-
was established in 2012; in 2016 the company has received a GMP certificate to produce bacteriophages as medicinal products;
-
the main research and production activities include the production of bacteria-based products, mainly in three main segments:
i) bacterial lysates,
ii) phage lysates and
iii) bacterial enzymes
FOR INVESTORS
Do you identify DUOFAG® as an ideal subject for investment?
MB Pharma opens an opportunity to invest to the DUOFAG® clinical trials.
For further discussions, contact us.